JP2016530291A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016530291A5 JP2016530291A5 JP2016539645A JP2016539645A JP2016530291A5 JP 2016530291 A5 JP2016530291 A5 JP 2016530291A5 JP 2016539645 A JP2016539645 A JP 2016539645A JP 2016539645 A JP2016539645 A JP 2016539645A JP 2016530291 A5 JP2016530291 A5 JP 2016530291A5
- Authority
- JP
- Japan
- Prior art keywords
- metadoxine
- composition
- sustained release
- disorder
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RYKKQQUKJJGFMN-HVDRVSQOSA-N 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol;(2S)-5-oxopyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCC(=O)N1.CC1=NC=C(CO)C(CO)=C1O RYKKQQUKJJGFMN-HVDRVSQOSA-N 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 10
- 230000002459 sustained Effects 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 2
- 206010000117 Abnormal behaviour Diseases 0.000 claims 1
- 208000001914 Fragile X Syndrome Diseases 0.000 claims 1
- 108009000484 Fragile X Syndrome Proteins 0.000 claims 1
- 206010024094 Learning disease Diseases 0.000 claims 1
- 201000007185 autism spectrum disease Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 230000011273 social behavior Effects 0.000 claims 1
- 230000003442 weekly Effects 0.000 claims 1
Claims (9)
- 脆弱Ｘ症候群または関連障害の症状の処置または緩和のための、メタドキシンを含んでなる組成物。
- １００〜３０００ｍｇの間の総一日用量のメタドキシンを投与することを含んでなる、請求項１に記載の組成物。
- 前記メタドキシンが毎日、１日おきに、または毎週投与される、請求項１に記載の組成物。
- 前記メタドキシンが１日当たり１、２、または３種類の剤形で投与される、請求項１に記載の組成物。
- 前記メタドキシンが持続放出経口剤形で投与され、前記メタドキシンが徐放形態と即時放出形態の組合せとして処方される、請求項１に記載の組成物。
- （ａ）徐放形態が少なくとも８時間の前記メタドキシンの持続放出を提供し、かつ、
（ｂ）徐放メタドキシンと即時放出メタドキシンの相対比が約６０：４０〜８０：２０の間である、
請求項５に記載の組成物。 - 前記徐放メタドキシンと前記即時放出メタドキシンの相対比が約６５：３５である、請求項６に記載の組成物。
- 前記症状が学習障害または社会的行動障害である、請求項１に記載の組成物。
- 前記関連障害が自閉症スペクトラム障害である、請求項１に記載の組成物。
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361875384P | 2013-09-09 | 2013-09-09 | |
| US61/875,384 | 2013-09-09 | ||
| US14/038,258 | 2013-09-26 | ||
| US14/038,258 US20150073023A1 (en) | 2013-09-09 | 2013-09-26 | Method Of Treating Fragile X Syndrome And Related Disorders |
| US201461991351P | 2014-05-09 | 2014-05-09 | |
| US61/991,351 | 2014-05-09 | ||
| PCT/IB2014/002398 WO2015033224A2 (en) | 2013-09-09 | 2014-09-09 | Methods of treating fragile x syndrome and related disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016530291A JP2016530291A (ja) | 2016-09-29 |
| JP2016530291A5 true JP2016530291A5 (ja) | 2017-10-19 |
Family
ID=52629036
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016540930A Pending JP2016530536A (ja) | 2013-09-09 | 2014-09-09 | 療法に対する奏効性の決定方法 |
| JP2016539645A Pending JP2016530291A (ja) | 2013-09-09 | 2014-09-09 | 脆弱ｘ症候群および関連障害の処置方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016540930A Pending JP2016530536A (ja) | 2013-09-09 | 2014-09-09 | 療法に対する奏効性の決定方法 |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP3044589A1 (ja) |
| JP (2) | JP2016530536A (ja) |
| KR (2) | KR20160086818A (ja) |
| CN (2) | CN105517546A (ja) |
| AU (2) | AU2014315026A1 (ja) |
| CA (2) | CA2923421A1 (ja) |
| EA (2) | EA201690557A1 (ja) |
| IL (2) | IL244343A0 (ja) |
| MX (2) | MX2016003006A (ja) |
| SG (2) | SG11201601830PA (ja) |
| TW (2) | TW201606304A (ja) |
| WO (2) | WO2015035402A1 (ja) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109021022B (zh) * | 2013-07-31 | 2021-04-16 | Udc 爱尔兰有限责任公司 | 发光的二氮杂苯并咪唑碳烯金属配合物 |
| US20150073023A1 (en) | 2013-09-09 | 2015-03-12 | Alcobra Ltd. | Method Of Treating Fragile X Syndrome And Related Disorders |
| CN108538365A (zh) * | 2017-03-24 | 2018-09-14 | 华东师范大学 | 一种基于数据分析技术的自闭症社交能力评估系统 |
| JP2021524836A (ja) * | 2018-04-13 | 2021-09-16 | ヒールクス リミテッドＨｅａｌｘ Ｌｉｍｉｔｅｄ | 脆弱ｘ症候群の治療 |
| KR20190121569A (ko) * | 2018-04-18 | 2019-10-28 | 건국대학교 글로컬산학협력단 | 아그마틴 및 이의 약학적으로 허용 가능한 염을 포함하는 취약 x 증후군 예방 또는 치료용 약학조성물 |
| JP7387179B2 (ja) * | 2018-06-07 | 2023-11-28 | オービッド・セラピューティクス・インコーポレイテッド | 発達障害の処置における（ｓ）－３－アミノ－４－（ジフルオロメチレニル）シクロペンタ－１－エン－１－カルボン酸および関連化合物、（１ｓ，３ｓ）－３－アミノ－４－（ジフルオロメチリデン）シクロペンタン－１－カルボン酸ならびにビガバトリンの使用 |
| WO2021141426A1 (ko) * | 2020-01-08 | 2021-07-15 | 건국대학교 글로컬산학협력단 | 리수리드 화합물을 유효성분으로 포함하는 취약 x 증후군 또는 관련 발달 장애 치료용 조성물 |
| WO2021158059A1 (ko) * | 2020-02-07 | 2021-08-12 | 건국대학교 글로컬산학협력단 | 릴메니딘 화합물을 유효성분으로 포함하는 취약 x 증후군 또는 관련 발달 장애 치료용 조성물 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1131856B (it) | 1980-06-30 | 1986-06-25 | Baldacci Lab Spa | Composizione farmaceutica per il trattamento di intossicazioni alcooliche |
| US20020155170A1 (en) * | 2000-11-30 | 2002-10-24 | Walsh William John | Nutrient supplements and methods for treating autism and for preventing the onset of autism |
| IL187159A0 (en) | 2007-07-03 | 2009-02-11 | Gur Megiddo | Use of metadoxine in relief of alcohol intoxication |
| CA2766107A1 (en) * | 2009-06-25 | 2010-12-29 | Alcobra Ltd. | A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition |
-
2014
- 2014-09-05 TW TW103130859A patent/TW201606304A/zh unknown
- 2014-09-05 TW TW103130856A patent/TW201605443A/zh unknown
- 2014-09-09 JP JP2016540930A patent/JP2016530536A/ja active Pending
- 2014-09-09 CN CN201480049671.5A patent/CN105517546A/zh active Pending
- 2014-09-09 CA CA2923421A patent/CA2923421A1/en not_active Abandoned
- 2014-09-09 AU AU2014315026A patent/AU2014315026A1/en not_active Abandoned
- 2014-09-09 SG SG11201601830PA patent/SG11201601830PA/en unknown
- 2014-09-09 AU AU2014316779A patent/AU2014316779A1/en not_active Abandoned
- 2014-09-09 EP EP14776939.2A patent/EP3044589A1/en not_active Withdrawn
- 2014-09-09 KR KR1020167009042A patent/KR20160086818A/ko not_active Application Discontinuation
- 2014-09-09 CN CN201480060722.4A patent/CN105917225A/zh active Pending
- 2014-09-09 CA CA2922901A patent/CA2922901A1/en not_active Abandoned
- 2014-09-09 EA EA201690557A patent/EA201690557A1/ru unknown
- 2014-09-09 WO PCT/US2014/054816 patent/WO2015035402A1/en active Application Filing
- 2014-09-09 SG SG11201601605YA patent/SG11201601605YA/en unknown
- 2014-09-09 EP EP14830858.8A patent/EP3043792A2/en not_active Withdrawn
- 2014-09-09 WO PCT/IB2014/002398 patent/WO2015033224A2/en active Application Filing
- 2014-09-09 MX MX2016003006A patent/MX2016003006A/es unknown
- 2014-09-09 MX MX2016003002A patent/MX2016003002A/es unknown
- 2014-09-09 JP JP2016539645A patent/JP2016530291A/ja active Pending
- 2014-09-09 EA EA201690559A patent/EA201690559A1/ru unknown
- 2014-09-09 KR KR1020167009040A patent/KR20160078956A/ko not_active Application Discontinuation
-
2016
- 2016-02-29 IL IL244343A patent/IL244343A0/en unknown
- 2016-03-06 IL IL244453A patent/IL244453A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016530291A5 (ja) | ||
| HRP20210819T1 (hr) | Fenfluramin za uporabu u liječenju dravet sindroma | |
| JP2012193216A5 (ja) | ||
| JP2018193377A5 (ja) | ||
| JP2010248252A5 (ja) | ||
| EA201690107A1 (ru) | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе | |
| MY181159A (en) | Sublingual and buccal film compositions | |
| JP2015057451A5 (ja) | ||
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| JP2014111603A5 (ja) | ||
| JP2015515475A5 (ja) | ||
| JP2010285439A5 (ja) | ||
| BR112015018168A2 (pt) | inibidores de rock suaves | |
| JP2015517488A5 (ja) | ||
| JP2013505205A5 (ja) | ||
| JP2013231087A5 (ja) | ||
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| JP2015525757A5 (ja) | ||
| MX2013003635A (es) | Compuestos de n-heteroarilo. | |
| AR091351A1 (es) | Formulaciones de bromocriptina, metodo para mejorar el control glucemico y metodo para la fabricacion | |
| MX340188B (es) | Elaboracion de granulos sin activos y tabletas que comprenden los mismos. | |
| JP2013541583A5 (ja) | ||
| BR112014014795A2 (pt) | sistema de pélete de multiunidade de liberação imediata | |
| JP2014507475A5 (ja) | ||
| BR112014009580A2 (pt) | composição farmacêutica de omeprazol |